Cargando…
Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy
Diabetes-driven retinal neurodegeneration has recently been shown to be involved in the initial phases of diabetic retinopathy, raising the possibility of setting up a preventive strategy based on early retinal neuroprotection. To make this possible, it is crucial to identify a biomarker for early r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454227/ https://www.ncbi.nlm.nih.gov/pubmed/37628852 http://dx.doi.org/10.3390/ijms241612672 |
_version_ | 1785096138707173376 |
---|---|
author | Zerbini, Gianpaolo Maestroni, Silvia Viganò, Ilaria Mosca, Andrea Paleari, Renata Gabellini, Daniela Galbiati, Silvia Rama, Paolo |
author_facet | Zerbini, Gianpaolo Maestroni, Silvia Viganò, Ilaria Mosca, Andrea Paleari, Renata Gabellini, Daniela Galbiati, Silvia Rama, Paolo |
author_sort | Zerbini, Gianpaolo |
collection | PubMed |
description | Diabetes-driven retinal neurodegeneration has recently been shown to be involved in the initial phases of diabetic retinopathy, raising the possibility of setting up a preventive strategy based on early retinal neuroprotection. To make this possible, it is crucial to identify a biomarker for early retinal neurodegeneration. To this end, in this study, we verified and confirmed that, in the Akita mouse model of diabetes, the thinning of the retinal nerve fiber layer/ganglion cell layer (the RNFL/GCL—the layer that contains the retinal ganglion cells) precedes the death of these same cells, suggesting that this dysfunction is a possible biomarker of retinal neurodegeneration. We then confirmed the validity of this assumption by starting a neuroprotective treatment (based on nerve growth factor eye drops) in concert with the first demonstration of RNFL/GCL thinning. In this way, it was possible not only to avoid the loss of retinal ganglion cells but also to prevent the subsequent development of the microvascular stage of diabetic retinopathy. In conclusion, in the case of diabetes, the thinning of the RNFL/GCL appears to be both a valid biomarker and a pharmacological target of diabetic retinopathy; it precedes the development of vascular dysfunctions and represents the ideal starting point for prevention. |
format | Online Article Text |
id | pubmed-10454227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104542272023-08-26 Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy Zerbini, Gianpaolo Maestroni, Silvia Viganò, Ilaria Mosca, Andrea Paleari, Renata Gabellini, Daniela Galbiati, Silvia Rama, Paolo Int J Mol Sci Article Diabetes-driven retinal neurodegeneration has recently been shown to be involved in the initial phases of diabetic retinopathy, raising the possibility of setting up a preventive strategy based on early retinal neuroprotection. To make this possible, it is crucial to identify a biomarker for early retinal neurodegeneration. To this end, in this study, we verified and confirmed that, in the Akita mouse model of diabetes, the thinning of the retinal nerve fiber layer/ganglion cell layer (the RNFL/GCL—the layer that contains the retinal ganglion cells) precedes the death of these same cells, suggesting that this dysfunction is a possible biomarker of retinal neurodegeneration. We then confirmed the validity of this assumption by starting a neuroprotective treatment (based on nerve growth factor eye drops) in concert with the first demonstration of RNFL/GCL thinning. In this way, it was possible not only to avoid the loss of retinal ganglion cells but also to prevent the subsequent development of the microvascular stage of diabetic retinopathy. In conclusion, in the case of diabetes, the thinning of the RNFL/GCL appears to be both a valid biomarker and a pharmacological target of diabetic retinopathy; it precedes the development of vascular dysfunctions and represents the ideal starting point for prevention. MDPI 2023-08-11 /pmc/articles/PMC10454227/ /pubmed/37628852 http://dx.doi.org/10.3390/ijms241612672 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zerbini, Gianpaolo Maestroni, Silvia Viganò, Ilaria Mosca, Andrea Paleari, Renata Gabellini, Daniela Galbiati, Silvia Rama, Paolo Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy |
title | Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy |
title_full | Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy |
title_fullStr | Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy |
title_full_unstemmed | Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy |
title_short | Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy |
title_sort | progressive thinning of retinal nerve fiber layer/ganglion cell layer (rnfl/gcl) as biomarker and pharmacological target of diabetic retinopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454227/ https://www.ncbi.nlm.nih.gov/pubmed/37628852 http://dx.doi.org/10.3390/ijms241612672 |
work_keys_str_mv | AT zerbinigianpaolo progressivethinningofretinalnervefiberlayerganglioncelllayerrnflgclasbiomarkerandpharmacologicaltargetofdiabeticretinopathy AT maestronisilvia progressivethinningofretinalnervefiberlayerganglioncelllayerrnflgclasbiomarkerandpharmacologicaltargetofdiabeticretinopathy AT viganoilaria progressivethinningofretinalnervefiberlayerganglioncelllayerrnflgclasbiomarkerandpharmacologicaltargetofdiabeticretinopathy AT moscaandrea progressivethinningofretinalnervefiberlayerganglioncelllayerrnflgclasbiomarkerandpharmacologicaltargetofdiabeticretinopathy AT palearirenata progressivethinningofretinalnervefiberlayerganglioncelllayerrnflgclasbiomarkerandpharmacologicaltargetofdiabeticretinopathy AT gabellinidaniela progressivethinningofretinalnervefiberlayerganglioncelllayerrnflgclasbiomarkerandpharmacologicaltargetofdiabeticretinopathy AT galbiatisilvia progressivethinningofretinalnervefiberlayerganglioncelllayerrnflgclasbiomarkerandpharmacologicaltargetofdiabeticretinopathy AT ramapaolo progressivethinningofretinalnervefiberlayerganglioncelllayerrnflgclasbiomarkerandpharmacologicaltargetofdiabeticretinopathy |